Literature DB >> 3905790

Synthesis and biochemical characterization of a photoactivatable, iodinatable, cleavable bacterial lipopolysaccharide derivative.

H W Wollenweber, D C Morrison.   

Abstract

A method for the synthesis of a photoactivatable, iodinatable, and thiol-cleavable derivative of bacterial lipopolysaccharide (LPS) is described using sulfosuccinimidyl 2-(p-azidosalicylamido)-1,3'-dithiopropionate. The method described is applicable to LPS from both smooth and rough bacteria. Evidence is presented that the coupling reaction occurs primarily to phosphoethanolamine residues localized to the inner core region of the LPS. Radioiodination of the derivatized LPS results in a product with a specific activity of 1.8-2.5 microCi/micrograms. Experiments comparing the activity of native and derivatized S-form LPS suggest that the synthesis has not introduced major alterations in the biological properties of the LPS. The feasibility of this derivatized LPS as a molecular probe to investigate LPS binding targets in biological systems is suggested by experiments showing ultraviolet light-dependent cross-linking, thiol-dependent cleavage, and subsequent transfer of radioiodine to both monoclonal anti-LPS antibody and bovine serum albumin. The latter interaction has been demonstrated to be highly selective in protein mixtures containing serum albumin in solution with LPS.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3905790

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide.

Authors:  T Kawata; J R Bristol; D P Rossignol; J R Rose; S Kobayashi; H Yokohama; A Ishibashi; W J Christ; K Katayama; I Yamatsu; Y Kishi
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

2.  Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins.

Authors:  J R Rose; M A Mullarkey; W J Christ; L D Hawkins; M Lynn; Y Kishi; K M Wasan; K Peteherych; D P Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Identification and characterization of lipopolysaccharide-binding proteins on human peripheral blood cell populations.

Authors:  J L Halling; D R Hamill; M G Lei; D C Morrison
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

4.  Lymphocyte receptors for pertussis toxin.

Authors:  C G Clark; G D Armstrong
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

5.  Killing of gram-negative bacteria by lactoferrin and lysozyme.

Authors:  R T Ellison; T J Giehl
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

6.  Endotoxic-lipopolysaccharide-specific binding proteins on lymphoid cells of various animal species: association with endotoxin susceptibility.

Authors:  D J Roeder; M G Lei; D C Morrison
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

7.  Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14.

Authors:  J Pugin; C C Schürer-Maly; D Leturcq; A Moriarty; R J Ulevitch; P S Tobias
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

8.  Evidence that lipopolysaccharide and pertussis toxin bind to different domains on the same p73 receptor on murine splenocytes.

Authors:  M G Lei; D C Morrison
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

9.  Suppression of murine endotoxin response by E5531, a novel synthetic lipid A antagonist.

Authors:  S Kobayashi; T Kawata; A Kimura; K Miyamoto; K Katayama; I Yamatsu; D P Rossignol; W J Christ; Y Kishi
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Antibody-independent activation of the classical pathway of human serum complement by lipid A is restricted to re-chemotype lipopolysaccharide and purified lipid A.

Authors:  S W Vukajlovich
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.